FDA rejects Celgene’s NDA for relapsing multiple sclerosis drug ozanimod

This article was originally published here

The US Food and Drug Administration (FDA) has rejected Celgene’s new drug application (NDA) for relapsing multiple sclerosis drug, ozanimod.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply